Earnings ·
Opus Genetics reported a net loss of $8.1 million, or ($0.08) per basic share, for the second quarter ended June 30…
IRDOpus Genetics, Inc.
Opus Genetics reported a net loss of $8.1 million, or ($0.08) per basic share, for the second quarter ended June 30, 2026, compared to a $7.4 million loss in the prior year period. Revenue declined to $0.8 million from $2.9 million as R&D expenses rose to $11.2 million due to higher manufacturing and clinical costs associated with inherited retinal disease programs. The company holds $88.8 million in cash, projecting a runway into 2029. Clinically, the OPGx-LCA5 registrational trial enrollment is complete with dosing planned for Q4 2026, while OPGx-BEST1 Cohort 1 topline data is expected in September 2026. Opus Genetics operates as a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases.